Optimization of recombinant human erythropoietin therapy after allogeneic hematopoietic stem cell transplantation

Experimental Hematology

Volumn 30, Issue 6, 2002, Pages 546-554

  Baron, Frédéric ^a   Sautois, Brieuc ^a   Baudoux, Etienne ^a   Matus, Geoffrey ^a   Fillet, Georges ^a   Beguin, Yves ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE CALCULATION; DRUG SENSITIVITY; ERYTHROCYTE; FATIGUE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; RETICULOCYTE; SCHOOL CHILD; TIME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CHILD; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; THROMBOCYTOSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036278921     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(02)00795-6     Document Type: Article

References (43)

1. Erythropoietin titers in health and disease
2. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin
3. Marked erythropoietin increase before fall in Hb after treatment with cytostatic drugs suggests mechanism other than anaemia for stimulation
4. Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation
5. Changes in serum erythropoietin levels during allogeneic bone marrow transplantation
6. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: Implications for erythropoietin therapy in this setting
7. Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy
8. Impaired erythropoietin response to anemia after bone marrow transplantation
9. Inadequate erythropoietin production in allogeneic bone marrow transplant patients
10. Serum erythropoietin levels in patients undergoing autologous bone marrow transplantation
11. Influence of marrow erythropoietic activity on serum erythropoietin levels after autologous hematopoietic stem cell transplantation
12. Serum erythropoietin during autologous bone marrow transplantation: Relationship to measures of erythroid activity
13. Circulating erythropoietin levels after bone marrow transplantation: Inappropriate response to anemia in allogeneic transplants
14. Dynamics of erythropoietic recovery after bone marrow transplantation: Role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants
15. Serum erythropoietin changes in autologous and allogeneic bone marrow transplant patients
16. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation
17. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: Effect on erythroid repopulation in autologous versus allogeneic transplants
18. A controlled trial of recombinant human erythropoietin after bone marrow transplantation
19. High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: Non-haematological, haematological toxicities and role of growth factor administration
20. The combination of erythropoietin and granulocyte colony-stimulating factor increases the rate of haemopoietic recovery with clinical benefit after peripheral blood progenitor cell transplantation
21. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: A randomized trial
22. A randomized study of erythropoietin and granulocyte colony-stimulating factor (G-CSF) versus placebo and G-CSF for patients with Hodgkin's and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation
23. Stimulation of erythroid engraftment by recombinant human erythropoietin in ABO-compatible, HLA-identical, allogeneic bone marrow transplant patients
24. Effect of recombinant human erythropoietin after allogenic bone marrow transplantation
25. Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation
26. Erythropoietin treatment in allogeneic BMT accelerates erythroid reconstitution: Results of a prospective controlled randomized trial
27. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. The Australian Bone Marrow Transplant Study Group
28. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: Results of a randomised, double-blind study with high-dose erythropoietin
29. Pilot trial of combined administration of erythropoietin and granulocyte colony-stimulating factor to children undergoing allogeneic bone marrow transplantation
30. High doses of recombinant human erythropoietin fail to accelerate platelet reconstitution in allogeneic bone marrow transplantation. Results of a pilot study
31. Thiazole orange: A new dye for reticulocyte analysis
32. Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin
33. Impaired erythropoietin production in mice treated with cyclosporin A
34. Down-modulation of serum erythropoietin levels following cyclosporin A infusion (letter)
35. Effects of cyclosporin A on erythropoietin production by the human Hep3B hepatoma cell line
36. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: A randomized, controlled study
37. Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer
38. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: Dose finding and identification of predictors of response
39. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma. A randomized multicenter study
40. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer
41. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of erythroblasts during constant treatment with recombinant human erythropoietin
42. Prediction of response to treatment with recombinant human erythropoietin in anaemia associated with cancer
43. Use of recombinant human erythropoietin outside the setting of uremia